Weight Loss and Arthritis: A focus on patient-reported outcomes Obesity is associated with poorer physical function and treatment response in rheumatoid arthritis (RA). The ACR guideline on exercise, rehabilitation and diet supports discussing healthy body weight as part of https://t.co/GynYYRqC4T

Khanna et al. REDUCE-2 Phase 3 DB RCT. New URAT1 inhibitor Pozdeutinurad. Significantly more pts achieved SU <6 mg/dL with pozdeutinurad high dose (69.2%) and low dose (56.6%) vs PBO at month 6 (8.1%; both p<0.0001) No safety signals. @RheumNow #ACR26 Abstr#LB20 https://t.co/eU56QgXp2o

Park et al. Phase 2 RCT from Korea. Stem cell and cartilage acellular matrix combination injection for knee OA. Single injection provides 6-month benefits in pain, function, MRI findings, biomarkers vs placebo. @RheumNow #ACR26 Abstr#LB19 #ACRbest https://t.co/iw378MV2OM

ACR 2026 guidelines for management of OA 1. Self management programs: educate pts on the disease and involve them in their care. 2. PT/OT-Key! 3. Mobility aids if limited walking. 4. Exercise! all of them recommended. 5. Wt loss if hip/knee OA and overwt or obese 6. Topical https://t.co/JnbNaZ3CSw

We used a pathology foundation model to identify interpretable spatial “microniches” in RA synovial histology #ACR26 abst#1087. It reproduced established pathologic features and identified lymphocytic inflammation associated with ESR, tissue based precision rheumatology @RheumNow https://t.co/pJRnbczgWC

Is it ok to re-analyze a #negative #RCT in #Raynaud’s Likely yes to learn how to study Ph3 or abandon drug Abst#2907 -neg RCT in #RP w #cilnidipine a marketed anti hypertensive Some ‘trends’ Studied to inform Future RCT on dose, outcome measures #ACR26 @RheumNow @ACRheum https://t.co/3AoiZ3juk4

#H2H #RCTs in #PsA, #PsO Of #IL17i vs #IL23i /IL12/23i For #PsO IL23i>IL17i #guselkumab >secukinumab #Secukinumab>#ustekinumab for #HAQ DI in PsA #PsA #bimekizumab>#risankizumab depends on what you want as outcome #psoriasis v #psoriatic #arthritis #ACR26 @RheumNow #2804 https://t.co/kOQiC5O68Y

Anthone et al. MMP-7 associated with greater chest CT involvement and lower DLCO in multicenter, prospective RA-ILD cohort. ?utility as biomarker of RA-ILD severity. @RheumNow #ACR26 Abstr#2886 https://t.co/32kggO6VEF

SLE can permanently alter employment. In a cohort 1800pts followed a median 18 years, 84.3% of pts initially receiving disability benefits remained in that state. Renal, neuropsychiatric, endocrine and musculoskeletal damage predicted disability. @rheumnow #ACR26 Abstract #1266 https://t.co/9tzmAlJcx1

Who Gets Left Behind by New AxSpA Criteria? #ACR26 Abstract #2877: Dr. Carla Saad evaluated 1,602 patients. ASAS-SPARTAN 2025 criteria excluded 74 previously classified patients. Greater specificity, but at what cost? @RheumNow https://t.co/VAUsL7YuCE